UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Neurology, 2004-11, Vol.63 (9), p.1586-1590

2004

Volltextzugriff (PDF)

Vitamin D and multiple sclerosis-from epidemiology to prevention

Acta neurologica Scandinavica, 2015-07, Vol.132 (S199), p.56-61

2015

Volltextzugriff (PDF)

Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB11501 on multiple sclerosis risk

Neurology, 2010-04, Vol.74 (17), p.1365-1371

2010

Volltextzugriff (PDF)

Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis

Brain (London, England : 1878), 2024, Vol.147 (1), p.177-185

2024

Volltextzugriff (PDF)

Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis

European journal of neurology, 2024-10, Vol.31 (10), p.e16387-n/a

2024

Volltextzugriff (PDF)

An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study

Neurology, 2004-06, Vol.62 (12), p.2277-2282

2004

Volltextzugriff (PDF)

Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis

Brain (London, England : 1878), 2024, Vol.147 (10), p.3573-3582

2024

Volltextzugriff (PDF)

Managing Epstein‐Barr virus and other risk factors in MS—Future perspectives

Acta neurologica Scandinavica, 2017-11, Vol.136 (S201), p.31-33

Sundstrom, P

2017

Volltextzugriff (PDF)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.638

2022

Volltextzugriff (PDF)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.858

2022

Volltextzugriff (PDF)

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.352

2022

Volltextzugriff (PDF)

Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort

EUROPEAN JOURNAL OF NEUROLOGY, 2023, Vol.30 (Suppl. 1), p.54

2023

Volltextzugriff (PDF)

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.86

2022

Volltextzugriff (PDF)

Prevention of post‐dural puncture headache: a randomized controlled trial

European journal of neurology, 2020-05, Vol.27 (5), p.871-877

2020

Volltextzugriff (PDF)

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Genes and immunity, 2012-01, Vol.13 (1), p.14-20

2012

Volltextzugriff (PDF)

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Multiple sclerosis, 2014-02, Vol.20 (2), p.165-173

2014

Volltextzugriff (PDF)

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Volltextzugriff (PDF)

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.536

2019

Volltextzugriff (PDF)

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.327

2019

Volltextzugriff (PDF)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.623

2021

Volltextzugriff (PDF)

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.616

2021

Volltextzugriff (PDF)

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.612

2021

Volltextzugriff (PDF)

Automated determination of brain parenchymal fraction in multiple sclerosis

American journal of neuroradiology : AJNR, 2013-03, Vol.34 (3), p.498-504

2013

Volltextzugriff (PDF)

Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.763

2019

Volltextzugriff (PDF)

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Volltextzugriff (PDF)

1 – 25 von 1.171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.097)
Mit Volltextzugriff
(1.004)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(790)
Life Sciences & Biomedicine
(659)
Humans
(511)
Medicin Och Hälsovetenskap
(467)
Female
(334)
Male
(265)
Biological And Medical Sciences
(219)
Adult
(209)
Middle Aged
(185)
Medical Sciences
(146)
Aged
(133)
Animals
(122)
Neurosciences & Neurology
(104)
Risk Factors
(97)
Oncology
(86)
Clinical Neurology
(81)
Fundamental And Applied Biological Sciences. Psychology
(80)
Medical And Health Sciences
(77)
Physical Sciences
(77)
Clinical Medicine
(76)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(623)
EZB Electronic Journals Library
(579)
Journals@Ovid Ovid Full Text
(488)
IngentaConnect Journals
(445)
Single Journals
(229)
Wiley-Blackwell Journals
(201)
IngentaConnect Journals
(182)
Wiley Online Library
(164)
Elsevier ScienceDirect Journals Complete
(156)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(111)
SpringerLink
(93)
SAGE Publications
(82)
Oxford Journals
(74)
JSTOR
(68)
Taylor & Francis Online
(65)
Taylor & Francis Journals
(64)
Oxford Journals 2020 Medicine
(62)
Taylor & Francis
(55)
Nature
(50)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(49)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Multiple Sclerosis
(25)
Acta Neurologica Scandinavica
(17)
Science
(16)
International Journal Of Cancer
(15)
Multiple Sclerosis Journal
(14)
Neurology
(14)
Plos One
(13)
The Journal Of Physical Chemistry. B
(13)
European Heart Journal
(12)
Blood
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Vitamin D and multiple sclerosis-from epidemiology to prevention

Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB11501 on multiple sclerosis risk

Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis

Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis

An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study

Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis

Managing Epstein‐Barr virus and other risk factors in MS—Future perspectives

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

Prevention of post‐dural puncture headache: a randomized controlled trial

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

Automated determination of brain parenchymal fraction in multiple sclerosis

Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

Suchergebnisse filtern